Cerri S, Monari M, Guerrieri A, et al. - In a real-life setting, researchers compared pirfenidone and nintedanib in terms of efficacy as a treatment option for patients with idiopathic pulmonary fibrosis (IPF). They performed comparisons between patients with IPF who received either pirfenidone (n = 78) or nintedanib (n = 28) for 24 months, followed at two regional clinic centers in Italy, vs controls ie, patients who denied the treatment (n = 36). According to the findings of this real-life study, both pirfenidone and nintedanib displayed equal efficacy in reducing the decline of forced vital capacity and diffusing capacity of the lungs for carbon monoxide, compared with non-treated patients following 24 months of therapy; however, a more rapid decline in respiratory function was likely to be exhibited by patients with more advanced disease.